OX40 and p38MAPK inhibitor drugs already exist and used in other trials, so that's a good sign. Not sure what's stopping them from starting?

Actual paper: https://aacrjournals.org/cancerdiscovery/article-abstract/doi/10.1158/2159-8290.CD-22-0907/716615/p38MAPKa-stromal-reprogramming-sensitizes

Associated links:

https://www.mycancergenome.org/content/drugs/tavolimab/

https://en.wikipedia.org/wiki/P38_mitogen-activated_protein_kinases

https://pubmed.ncbi.nlm.nih.gov/18776065/